GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

INR 2303.2

(-1.26%)

Total Debt Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual total debt in 2023 was 186.65 Million INR , up 20.11% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly total debt in 2024 Q2 was 106.1 Million INR , down 0.0% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported annual total debt of 155.4 Million INR in 2022, down -22.6% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported annual total debt of 200.76 Million INR in 2021, down -42.02% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly total debt of 106.1 Million INR for 2024 Q2, down 0.0% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly total debt of 213.8 Million INR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Total Debt of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Total Debt	Total Debt Growth
2023	186.65 Million INR	20.11%
2022	155.4 Million INR	-22.6%
2021	200.76 Million INR	-42.02%
2020	346.26 Million INR	-17.24%
2019	418.4 Million INR	7076.67%
2018	5.83 Million INR	-41.05%
2017	9.89 Million INR	-37.99%
2016	15.95 Million INR	-32.79%
2015	23.73 Million INR	-23.83%
2014	31.15 Million INR	-24.79%
2013	41.42 Million INR	-9.82%
2012	45.93 Million INR	-6.36%
2011	49.05 Million INR	-4.97%
2010	51.61 Million INR	-4.97%
2009	54.31 Million INR	22818.99%
2008	237 Thousand INR	-99.59%
2007	58.24 Million INR	4.42%
2006	55.78 Million INR	13.51%
2005	49.14 Million INR	25.77%
2004	39.07 Million INR	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	- INR	-100.0%
2024 Q2	106.1 Million INR	0.0%
2023 Q2	213.8 Million INR	0.0%
2023 Q4	186.65 Million INR	0.0%
2023 FY	186.65 Million INR	20.11%
2023 Q3	- INR	-100.0%
2023 Q1	- INR	-100.0%
2022 Q2	232.4 Million INR	0.0%
2022 FY	155.4 Million INR	-22.6%
2022 Q4	155.4 Million INR	0.0%
2022 Q3	- INR	-100.0%
2022 Q1	- INR	-100.0%
2021 Q1	- INR	-100.0%
2021 Q4	200.76 Million INR	0.0%
2021 Q2	276.1 Million INR	0.0%
2021 FY	200.76 Million INR	-42.02%
2021 Q3	- INR	-100.0%
2020 Q4	346.26 Million INR	0.0%
2020 FY	346.26 Million INR	-17.24%
2020 Q2	439.9 Million INR	0.0%
2020 Q3	- INR	-100.0%
2020 Q1	- INR	-100.0%
2019 Q4	418.4 Million INR	0.0%
2019 FY	418.4 Million INR	7076.67%
2019 Q3	- INR	-100.0%
2019 Q2	431 Million INR	0.0%
2019 Q1	- INR	-100.0%
2018 Q4	5.83 Million INR	0.0%
2018 FY	5.83 Million INR	-41.05%
2018 Q1	- INR	0.0%
2017 FY	9.89 Million INR	-37.99%
2016 FY	15.95 Million INR	-32.79%
2015 FY	23.73 Million INR	-23.83%
2014 FY	31.15 Million INR	-24.79%
2013 FY	41.42 Million INR	-9.82%
2012 FY	45.93 Million INR	-6.36%
2011 FY	49.05 Million INR	-4.97%
2010 FY	51.61 Million INR	-4.97%
2009 FY	54.31 Million INR	22818.99%
2008 FY	237 Thousand INR	-99.59%
2007 FY	58.24 Million INR	4.42%
2006 FY	55.78 Million INR	13.51%
2005 FY	49.14 Million INR	25.77%
2004 FY	39.07 Million INR	0.0%

Peer Total Debt Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Total Debt	Total Debt Difference
Abbott India Limited	832.3 Million INR	77.574%
Cipla Limited	5.59 Billion INR	96.663%
Gland Pharma Limited	3.72 Billion INR	94.985%
Kopran Limited	992.28 Million INR	81.19%
Marksans Pharma Limited	2.44 Billion INR	92.352%
NGL Fine-Chem Limited	324.42 Million INR	42.467%
Pfizer Limited	945.4 Million INR	80.257%
Sanofi India Limited	190 Million INR	1.763%
SMS Pharmaceuticals Limited	2.8 Billion INR	93.352%
TTK Healthcare Limited	228.1 Million INR	18.174%